{"id":65384,"date":"2026-05-15T13:25:58","date_gmt":"2026-05-15T05:25:58","guid":{"rendered":"https:\/\/flcube.com\/?p=65384"},"modified":"2026-05-15T13:25:59","modified_gmt":"2026-05-15T05:25:59","slug":"chipscreen-biosciences-secures-macao-market-approval-for-bilessglu-chiglitazar-novel-ppar-pan-agonist-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65384","title":{"rendered":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes"},"content":{"rendered":"\n<p><strong>Chipscreen Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688321:SHA\">SHA: 688321<\/a>) announced it has received marketing clearance from the <strong>Pharmaceutical Administration Bureau of Macao SAR (ISAF)<\/strong> for <strong>Bilessglu (chiglitazar)<\/strong>, a novel <strong>non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist<\/strong> for the treatment of <strong>type 2 diabetes (T2D)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>ISAF, Macao SAR<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Bilessglu (chiglitazar)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type 2 diabetes (T2D)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>15 May 2026<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Macao Special Administrative Region<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>This approval marks Chipscreen&#8217;s first international market authorization for chiglitazar, representing a significant step in the company&#8217;s global expansion strategy beyond mainland China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Chiglitazar, a novel non-thiazolidinedione (non-TZD) PPAR \u03b1\/\u03b3\/\u03b4 pan-agonist<\/li>\n\n\n\n<li><strong>Design Principle:<\/strong> Deliberately engineered to produce <strong>moderate activity<\/strong> across all three PPAR subtypes<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Acts as an <strong>insulin sensitizer<\/strong> with potent effects on improving insulin sensitivity in T2D patients<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Avoids the safety concerns associated with traditional TZD-class PPAR\u03b3 agonists while maintaining efficacy<\/li>\n<\/ul>\n\n\n\n<p>Chiglitazar&#8217;s balanced pan-agonist profile represents a sophisticated approach to PPAR modulation, potentially offering improved glycemic control with a more favorable safety profile compared to selective PPAR\u03b3 agonists.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-timeline-amp-market-access\">Commercial Timeline &amp; Market Access<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Territory<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Approval<\/strong><\/td><td>2021<\/td><td>China<\/td><\/tr><tr><td><strong>NRDL Inclusion<\/strong><\/td><td>2023<\/td><td>China<\/td><\/tr><tr><td><strong>Metformin Combination Approval<\/strong><\/td><td>2024<\/td><td>China<\/td><\/tr><tr><td><strong>Macao Market Authorization<\/strong><\/td><td>2026<\/td><td>Macao SAR<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The drug&#8217;s inclusion in China&#8217;s <strong>National Reimbursement Drug List (NRDL)<\/strong> in 2023 significantly enhanced patient access and commercial uptake, establishing a strong foundation for international expansion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-opportunity\">Strategic Implications &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regional Gateway:<\/strong> Macao approval serves as a strategic entry point for broader international markets, particularly in Asia-Pacific regions with similar regulatory frameworks<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Chiglitazar competes in the insulin sensitizer segment alongside established TZDs like pioglitazone, but with potential safety advantages due to its non-TZD structure and moderate pan-agonist activity<\/li>\n\n\n\n<li><strong>Combination Therapy Potential:<\/strong> The 2024 Chinese approval for use with metformin demonstrates the drug&#8217;s versatility in combination regimens, which could be leveraged in Macao&#8217;s clinical practice<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> International expansion reduces Chipscreen&#8217;s dependence on the domestic Chinese market and opens new revenue streams<\/li>\n<\/ul>\n\n\n\n<p>The Macao approval validates chiglitazar&#8217;s regulatory acceptability outside mainland China and positions Chipscreen for potential additional international filings in 2026-2027.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding international expansion, regulatory approvals, and commercial opportunities for chiglitazar. Actual results may differ due to risks including market adoption, competitive dynamics, and regulatory requirements in additional territories.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688321_20260515_NFKJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688321_20260515_NFKJ.\"><\/object><a id=\"wp-block-file--media-87db47d9-4861-4c85-8642-1071432b32ff\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688321_20260515_NFKJ.pdf\">688321_20260515_NFKJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688321_20260515_NFKJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-87db47d9-4861-4c85-8642-1071432b32ff\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[659,39,15,1240],"class_list":["post-65384","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-chipscreen-biosciences","tag-diabetes","tag-product-approvals","tag-sha-688321"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65384\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65384\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T05:25:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-15T05:25:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes\",\"datePublished\":\"2026-05-15T05:25:58+00:00\",\"dateModified\":\"2026-05-15T05:25:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384\"},\"wordCount\":406,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chipscreen Biosciences\",\"Diabetes\",\"Product approvals\",\"SHA: 688321\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65384#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65384\",\"name\":\"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-15T05:25:58+00:00\",\"dateModified\":\"2026-05-15T05:25:59+00:00\",\"description\":\"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\\\/\u03b3\\\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65384\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65384#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65384","og_locale":"en_US","og_type":"article","og_title":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes","og_description":"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).","og_url":"https:\/\/flcube.com\/?p=65384","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-15T05:25:58+00:00","article_modified_time":"2026-05-15T05:25:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65384#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65384"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes","datePublished":"2026-05-15T05:25:58+00:00","dateModified":"2026-05-15T05:25:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65384"},"wordCount":406,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chipscreen Biosciences","Diabetes","Product approvals","SHA: 688321"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65384#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65384","url":"https:\/\/flcube.com\/?p=65384","name":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-15T05:25:58+00:00","dateModified":"2026-05-15T05:25:59+00:00","description":"Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical Administration Bureau of Macao SAR (ISAF) for Bilessglu (chiglitazar), a novel non-TZD peroxisome proliferator-activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 pan-agonist for the treatment of type 2 diabetes (T2D).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65384#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65384"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65384#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65384"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65384\/revisions"}],"predecessor-version":[{"id":65387,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65384\/revisions\/65387"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}